Artwork

Content provided by American Medical Association and JAMA Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by American Medical Association and JAMA Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Risankizumab for Ulcerative Colitis

15:49
 
Share
 

Manage episode 430214534 series 3382118
Content provided by American Medical Association and JAMA Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by American Medical Association and JAMA Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Ulcerative colitis can significantly decrease quality of life. A third of patients have persistent symptoms with tumor necrosis factor inhibitors and nearly 1 in 5 patients will be hospitalized within 5 years of diagnosis. Author Gilaad G. Kaplan, MD, MPH, of the University of Calgary joins JAMA Associate Editor John M. Inadomi, MD, to discuss Risankizumab for Ulcerative Colitis. Related Content:

  continue reading

816 episodes

Artwork
iconShare
 
Manage episode 430214534 series 3382118
Content provided by American Medical Association and JAMA Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by American Medical Association and JAMA Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Ulcerative colitis can significantly decrease quality of life. A third of patients have persistent symptoms with tumor necrosis factor inhibitors and nearly 1 in 5 patients will be hospitalized within 5 years of diagnosis. Author Gilaad G. Kaplan, MD, MPH, of the University of Calgary joins JAMA Associate Editor John M. Inadomi, MD, to discuss Risankizumab for Ulcerative Colitis. Related Content:

  continue reading

816 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide